Search for a trial

A prospective, multicenter, open-label extension of FUTURE 3 to assess the safety, tolerability and efficacy of the pediatric formulation of bosentan two versus three times a day in children with pulmonary arterial hypertension

To evaluate the long-term safety, tolerability and efficacy of the pediatric formulation of bosentan two versus three times a day in children with pulmonary arterial hypertension (PAH).

A long term extension trial of the Phase III lipid-lowering trials to assess the effect of long term dosing of inclisiran given as subcutaneous injections in subjects with high cardiovascular risk and elevated LDL-C (ORION-8)

The primary objectives are to evaluate:-The effect of inclisiran treatment on the proportion of subjects achieving prespecified low densitylipoprotein cholesterol (LDL-C) targets at end of study (EOS)-The safety and tolerability profile of long term…

An open-label, single arm, multicenter extension study to evaluate long-term safety and tolerability of inclisiran in participants with heterozygous or homozygous familial hypercholesterolemia who have completed the adolescent ORION-16 or ORION-13 studies (VICTORION-PEDS-OLE)

This study has been transitioned to CTIS with ID 2023-507278-41-00 check the CTIS register for the current data. The primary objective of the study is to evaluate the long-term safety and tolerability of inclisiran in participants with HeFH or HoFH

A Long-term Safety Extension Study of Mavacamten (MYK-461) in Adults
with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICKHCM
(MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE)

This study has been transitioned to CTIS with ID 2022-502858-14-00 check the CTIS register for the current data. primary objective:To assess the long-term safety and tolerability of mavacamten in participants with hypertrophic cardiomyopathy (HCM)…